82
out of 100
Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory
Karyopharm Therapeutics Claimed Company
Karyopharm is an innovation-driven pharmaceutical company whose core technology leverages the inhibition of nuclear export as a mechanism to treat patients with cancer and other medical conditions read more
Karyopharm Therapeutics Competitors
Karyopharm Therapeutics competitors include Takeda, Biogen, Alkermes, Amgen and Agios Pharmaceuticals. Karyopharm Therapeutics ranks 1st in CEO Score on Comparably vs its competitors. See below how Karyopharm Therapeutics compares to its competitors with CEO Rankings, Overall Culture Score, eNPS, Gender and Diversity Scores.
CEO Rank
1st
eNPS Rank
5th
Gender Rank
2nd
Diversity Rank
1st
See Karyopharm Therapeutics Culture vs Competitors:
- 1stKaryopharm Therapeutics79 / 100
- 2nd
Takeda76 / 100 - 3rd
Biogen75 / 100 - 4th
Alkermes73 / 100 - 5th
Amgen72 / 100 - 6th
Agios Pharmaceuticals60 / 100
Karyopharm Therapeutics Competitors at a Glance
CEO Ratings Comparison
Karyopharm Therapeutics' CEO Score Ranks 1st
52 Employees at Karyopharm Therapeutics rate Richard Paulson a 82 out of 100, which ranks them 1st out of Karyopharm Therapeutics' competitors. Last rating was months ago.
- 2nd
Christophe WeberTakeda78out of 100180 Employees at Takeda rate Christophe Weber a 78 out of 100, which ranks them 2nd out of Karyopharm Therapeutics' competitors. Last rating was 4 days ago.
- 3rd
Robert BradwayAmgen77out of 100243 Employees at Amgen rate Robert Bradway a 77 out of 100, which ranks them 3rd out of Karyopharm Therapeutics' competitors. Last rating was months ago.
- 4th
Richard PopsAlkermes74out of 10028 Employees at Alkermes rate Richard Pops a 74 out of 100, which ranks them 4th out of Karyopharm Therapeutics' competitors. Last rating was months ago.
- 5th
Michel VounatsosBiogen66out of 100143 Employees at Biogen rate Michel Vounatsos a 66 out of 100, which ranks them 5th out of Karyopharm Therapeutics' competitors. Last rating was months ago.
- 6th
Jackie FouseAgios Pharmaceuticals56out of 1009 Employees at Agios Pharmaceuticals rate Jackie Fouse a 56 out of 100, which ranks them 6th out of Karyopharm Therapeutics' competitors. Last rating was months ago.
Overall Culture Score Comparison
Karyopharm Therapeutics Ranks 1st in Overall Culture Score
90 Employees rate Karyopharm Therapeutics' Overall Culture a 79/100, which ranks it 1st against its competitors. Overall Culture scores are aggregated from all of the questions employees at a company answer on Comparably.
eNPS Comparison
Karyopharm Therapeutics Ranks 5th in Employee Net Promoter Score
90 Employees rate Karyopharm Therapeutics' Employee Net Promoter Score a 10, which ranks it 5th against its competitors, below Biogen. Employee Net Promoter score tracks employees' overall score to this question - “On a scale from 0-10, how likely are you to recommend working at Karyopharm Therapeutics to a friend?”.
Gender Score Comparison
Karyopharm Therapeutics Ranks 2nd in Gender Score
58 Employees rate Karyopharm Therapeutics' Gender Score a 79/100, which ranks it 2nd against its competitors, below Alkermes. The Gender Score tracks how positively women rate their experience at Karyopharm Therapeutics.
Diversity Score Comparison
Karyopharm Therapeutics Ranks 1st in Diversity Score
29 Employees rate Karyopharm Therapeutics' Diversity Score a 76/100, which ranks it 1st against its competitors. The Diversity Score tracks how positively diverse employees rate their experience at Karyopharm Therapeutics.
Rate your experience with Karyopharm Therapeutics
Anonymously Rate your Experience with Karyopharm Therapeutics×